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Abstract
Introduction
Current clinical trials utilize mesenchymal stromal cells (MSCs) expanded in culture, howev-
er these interventions carry considerable costs and concerns pertaining to culture-induced
losses of potency. This study assessed the feasibility of new clinical-grade technology to
obtain uncultured MSC isolates from three human intra-osseous tissue sources based on
immunomagnetic selection for CD271-positive cells.
Materials and Methods
MSCs were isolated from bone marrow (BM) aspirates or surgical waste materials; enzy-
matically digested femoral heads (FHs) and reamer irrigator aspirator (RIA) waste fluids.
Flow cytometry for the CD45−/lowCD73+CD271+ phenotype was used to evaluate uncul-
tured MSCs before and after selection, and to measure MSC enrichment in parallel to colo-
ny forming-unit fibroblast assay. Trilineage differentiation assays and quantitative
polymerase chain-reaction for key transcripts involved in bone regeneration was used to as-
sess the functional utility of isolated cells for bone repair.
Results
Uncultured CD45−/lowCD271+ MSCs uniformly expressed CD73, CD90 and CD105 but
showed variable expression of MSCA-1 and SUSD2 (BM>RIA>FH). MSCs were enriched
over 150-fold from BM aspirates and RIA fluids, whereas the highest MSC purities were ob-
tained from FH digests. Enriched fractions expressed increased levels of BMP-2, COL1A2,
VEGFC, SPARC and CXCL12 transcripts (BM>RIA>FH), with the highest up-regulation
detected for CXCL12 in BM (>1300-fold). Following culture expansion, CD271-selected
MSCS were tri-potential and phenotypically identical to plastic adherence-selected MSCs.
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Discussion
A CD271-based GMP-compliant immunomagnetic selection resulted in a substantial in-
crease in MSC purity and elevated expression of transcripts involved in bone formation,
vascularisation and chemo-attraction. Although this technology, particularly from RIA fluids,
can be immediately applied by orthopaedic surgeons as autologous therapy, further im-
provements in MSC purities and pre-clinical testing of product safety would be required to
develop this process for allogeneic applications.
Introduction
Culture expanded mesenchymal stromal cells (MSCs), also designated mesenchymal stem
cells, have undergone trials as therapeutic agents to treat a range of conditions including osteo-
genesis imperfecta [1], cartilage defects [2], acute myocardial infarction [3] and steroid resis-
tant graft versus host disease [4]. Thus far, expanded MSC therapy trials have resulted in
variable clinical outcomes, even for the same disease. This may be related to the MSC source or
route of administration or to differences in culture conditions and the degree of expansion em-
ployed [5–8]. Besides additional safety concerns associated with prolonged ex vivo cell cultiva-
tion including the risk of transformation [9–11], therapies utilising expanded cells must fulfil
good manufacturing practice (GMP) conditions which makes the costs of therapies prohibi-
tively high [12].
Conversely, uncultured cells, including CD34 selected or CD3, CD19 depleted cellular prod-
ucts following CliniMACS cell selection, have been used for haematopoietic stem cell trans-
plantation for decades and have revolutionized the treatment of haematological diseases and
saved the lives of thousands of patients [13]. There is therefore a strong impetus to develop
similar clinical-grade procedures for the isolation of uncultured MSCs, especially given the po-
tency and differentiation potentials that such MSCs may possess [14].
Although there have been attempts to increase MSC purity by physical means [15], positive
selection based on a specific MSC marker offers an appealing alternative. Because MSCs are
very rare in BM aspirates [16–19], the isolation of pure uncultured BMMSCs in the ‘research-
scale’ settings is best achieved by cell sorting with a combination of positive and negative mark-
ers [17,20–23]. Amongst a number of positive markers proposed in the past [24–26], CD271
offers unique selectivity, defined as the least cross-reactivity with contaminating haematopoie-
tic-lineage cells [7,17,23,27,28]. This is highly advantageous for the establishment of a single
marker-based, immunomagnetic enrichment procedure.
Femoral Heads (FH) removed as part of total hip replacement surgery, represent a potential
MSC source that is currently discarded but could be used in autologous settings to strengthen
implant integration with the remaining bone [29,30]. We and others have previously demon-
strated that enzymatic digestion of FH bone releases large numbers of MSCs that have a similar
phenotype to MSCs in BM aspirates [31,32]. Reamer irrigator aspirator (RIA) waste fluid is an-
other surgical waste by-product that is rich in MSCs, which is currently discarded [33–35]. It is
a particularly attractive source of MSCs since unlike FHs, it does not require enzymatic diges-
tion and can be used in autologous settings in complex bone reconstruction procedures.
This study therefore investigated the potential of clinical-grade anti-CD271 microbeads, in
combination with the CliniMACS device, to isolate human uncultured MSCs from BM aspi-
rates. Our secondary aim was to investigate whether this technology could be used to enrich
Clinical-Grade Isolation of Uncultured Mesenchymal Stromal Cells
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MSCs from other intra-osseous sources, namely the FH digests and RIA waste fluid [32,36],
both waste products of surgical interventions.
Materials and Methods
Ethics statement
All patients gave informed written consent and research was carried out in compliance with
the Helsinki Declaration. Ethics committee approval for this study was obtained from the local
National Health Service Research & Development Department, National Research Ethics Ser-
vice, Leeds East and West Research Ethics Committees under permit numbers 06/Q1206/127
and 07/Q1205/27 respectively.
Patient cohorts
BM aspirates were obtained from patients undergoing elective orthopaedic surgery or were sur-
plus BM donated by healthy donors, for haematopoietic stem cell transplantation (n = 23, me-
dian age 38, range: 4–72). FHs were collected from patients with osteoarthritis admitted for
total hip arthroplasty (n = 6, median age 70, range: 58–81). RIA waste fluid (mean volume
867ml) were obtained from patients admitted for the treatment of fracture non-union involv-
ing autologous bone grafting (n = 6, median age 38, range: 28–63).
CD271 positive selection using QuadroMACS for functional
characterisation
Mononuclear cells (MNCs) isolated from BM aspirates, FHs and RIA waste fluid using Lym-
phoprep reagent (Axis-Shield, Oslo, Norway) were labelled with clinical grade anti-CD271
microbeads (Miltenyi Biotec GmbH, Germany), according to the manufacturer’s instructions.
These consist of murine anti-CD271 monoclonal antibodies (clone information confidential)
conjugated to superparamagnetic iron dextran particles. Once labelled, cells were separated
into positive and negative fractions using the QuadroMACS system (Miltenyi Biotec). Cells
from the positive fraction were seeded into a T25 flask (Corning, NY, USA) and cultured in
GMP compliant MSC expansion mediumMSCGM Bulletkit (Lonza, Berkshire, UK). Three
days later, culture medium was replaced and subsequently changed twice weekly. Once the
cells (now denoted CD271-MSC) reached 80% confluence, the adherent cells were harvested
with 0.25% trypsin/1mM ethylenediaminetetraacetic acid (EDTA) solution (Sigma-Aldrich,
Dorset, UK) and passaged at the seeding density of 4x103/cm2 for further expansion. Control
plastic adherent MSCs (PA-MSC) were initiated according to standard protocols [36] and pas-
saged using the same seeding density as CD271-MSCs. At each passage cell population dou-
bling (PD) time was calculated.
To investigate MSC chondrogenic, osteogenic and adipogenic potentials, cells were centri-
fuged in chondrogenic pellets (2x105cells/pellet) or seeded into 6-well plates (osteogenic and
adipogenic seeding density of 2x104/well and 2x105/well, respectively). Cells were cultured in
either StemMACS ChondroDiff Media, StemMACS OsteoDiff Media or StemMACS AdipoDiff
Media (all Miltenyi Biotec) with twice-weekly media changes. After 21 days of differentiation,
chondrogenic pellets were fixed in 10% formalin, embedded in paraffin and 5μm sections were
stained with 0.1% Alcian Blue to detect proteoglycan deposition. Osteogenic cultures were first
stained with alkaline phosphatase substrate solution followed by a 1-hour treatment with 3%
silver nitrate to detect mineralization. Adipogenic cultures were fixed in 60% isopropanol be-
fore being stained with Oil Red O solution. Images were captured using a Zeiss Axio Imager II
(Carl Zeiss) and processed using NIS Elements Imaging Software version 4.0 (Nikon).
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Cell phenotyping
Phenotypic analysis of cells from BM, FH and RIA was carried out using flow cytometry. Sam-
ples were incubated with antibodies or isotype controls in FACS buffer (PBS pH7.4, 1% bovine
serum albumin) according to the manufacturer’s instructions. In each case 4,6-diamidino-2-
phenylindole (DAPI, Sigma-Aldrich) or aqua dead cell stain (Life technologies, Paisley, UK)
was added prior to acquisition to exclude dead cells.
Previously selected, expanded PA-MSCs and CD271-MSCs from each passage were probed
for expression of CD73, CD105, CD90, CD34, CD45, CD19, CD14 and HLA-DR (Table 1)
[37]; this data was acquired using a BD FACSCanto II flow cytometer (BD). All data was ana-
lysed using FlowJo v7.6.5 software (Treestar, Oregon, USA).
MSCs identified by negative to low expression of CD45 and positive expression of CD271
(CD45−/lowCD271+) [16,32,34], as well as cells with positive expression of CD45 and low ex-
pression of CD271 (CD45+CD271low) were examined in detail. Expression of a range of cell
Table 1. Antibodies used.
Specificity Conjugate Clone Manufacturer
Cultured MSC phenotype
CD14 FITC MφP9 BD
CD19 FITC HIB19 BD
CD34 FITC 581 BD
CD45 FITC 2D1 BD
CD73 PE AD2 BD
CD90 PerCP Cy5.5 5E10 BD
CD105 APC 266 BD
HLA-DR APC-H7 L243 BD
Extended phenotyping
CD3 V450 UCHT1 BD
CD14 PE M5E2 BD
CD19 Alexa fluor 700 HIB19 BD
CD31 BV610 WM59 Biolegend
CD34 APC 8G12 BD
CD45 PEcy7 HI30 BD
CD45 BV780 H130 Biolegend
CD73 PerCP Cy5.5 AD2 Mitenyi Biotec
CD90 PECy7 5E10 BD
CD105 FITC 43A4E1 Mitenyi Biotec
CD146 FITC 3A6 BD
CD271 APC ME20.4-1H4 Mitenyi Biotec
CD271 PE Vio770 ME20.4-1H4 Mitenyi Biotec
CD235a PE GA-R2 BD
MSCA-1 PE W8B2 Mitenyi Biotec
SUSD2 APC W5C5 Biolegend
Assessment of MSC content
CD45 PEcy7 HI30 BD
CD73 PE AD2 BD
CD271 APC ME20.4-1H4 Mitenyi Biotec
All antibodies used for phenotypic and enrichment analysis. All antibodies listed were monoclonal and raised in mouse.
doi:10.1371/journal.pone.0117855.t001
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surface markers was examined by incubation with monoclonal antibodies; CD3, CD14, CD19,
CD31, CD34, CD73, CD90, CD105, CD146, CD235a, mesenchymal stem cell antigen 1
(MSCA-1) and sushi domain containing 2 (SUSD2) [23,38,39] (Table 1). Antigen expression
on these populations was detected using a BD biosciences LSR II flow cytometer (BD Biosci-
ences, Oxford, UK).
Processing of BM aspirates, FH specimens and RIA fluids prior to
CliniMACS procedures
BM aspirates were harvested as previously described [16], with a minor modification in order
to ensure maximal MSC yields [40]. In brief, 5ml of BM was harvested from the first needle in-
sertion site, the needle was subsequently repositioned and a further 5ml was harvested; this was
repeated until a total volume of 20ml had been collected. A small volume, 1ml pre-enrichment
fraction (Pre) was retained for further analysis. A subset of these samples were taken forward
for CliniMACS enrichment, in which case the remaining sample was transferred into a sterile
600ml silicone transfer bag (Miltenyi Biotec). Samples not selected for enrichment were used
for direct MSC enumeration by flow cytometry using a CD45/CD271/CD73 antibody combi-
nation (Table 1), as previously described [16].
Once removed, FHs were bisected by the operating surgeon and stored immersed in sterile
saline overnight at 4°C. The following morning, FHs were removed from saline, broken into
small fragments (<1g) using a sterile Noviomagus bone mill (De Puy, Leeds, UK) and digested
with 600U/ml collagenase (Worthington, Lakewood, US) for 4 hours at 37°C. The liquid frac-
tion was passed through a 70μm filter (BD) to remove any remaining bone fragments and load-
ed into a 600ml transfer bag. The RIA waste fluid was directly transferred from the RIA
device’s collection bag into two 600ml transfer bags.
Clinical-grade MSC selection using CD271 microbeads and the
CliniMACS system
Prior to separation, cells were washed (400xg for 20 minutes) with GMP-grade PBS/EDTA
(Miltenyi Biotec) containing GMP-grade 5% w/v human serum albumin (HSA, Bio Products
Laboratory, Elstree, UK) and the supernatant was subsequently discarded using a closed sys-
tem, in which all sample or waste bags were connected using a TSCDI sterile tube welder and
detached using a sterile tube fuser (both from Terumo).
The volume in the transfer bag was next adjusted to 95ml by addition of PBS/EDTA/HSA
buffer as above, to which the contents of one vial of anti-CD271 microbeads was added. The
cell/bead mixture was incubated for 30 minutes on a tilting shaker at room temperature (RT).
Subsequently, a second wash was performed as above followed by volume adjustment to 95ml.
The transfer bag was next loaded onto the CliniMACS device and attached to a CliniMACS
tubing set. An automated protocol [41] was initiated resulting in separation into a positive
(Post) and a negative fractions. The Post fraction was eluted in 40ml of PBS/EDTA/HSA buffer
and concentrated by centrifugation to 1ml for further analysis of purity by flow cytometry and
CFU-F assay.
CFU-F assays were performed in duplicate as previously described [36]. Pre and Post frac-
tions were seeded at 1x105 and 1x104 nucleated cells/dish, respectively.
Flow cytometry to assess MSC content before and after selection
For the staining, 50μl of the Pre and Post enrichment fractions originating from BM aspirates,
enzymatically digested FH or RIA waste fluid were incubated with CD45, CD271, and CD73
Clinical-Grade Isolation of Uncultured Mesenchymal Stromal Cells
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(Table 1) for 15 minutes at RT at manufacturer’s recommended concentrations. Erythrocytes
were lysed by the addition of 2ml ammonium chloride solution (168mMNH2Cl, 10mM
KHCO3, 1mM EDTA, pH8.0) containing 0.5μg/ml DAPI (Sigma) and incubation at RT for 10
minutes. MSCs were defined as CD45-/lowCD271+CD73+ cells as described previously
[16,24,27].
Quantitative real time PCR
In order to examine the potential enrichment of key transcripts involved in bone regeneration
as a result of CD271 selection, RNA was isolated from the total cellular component of BM, FH
and RIA samples pre and post CD271 selection. Cells were lysed and RNA isolated using Nor-
gen Total RNA Isolation Kit (Geneflow, Lichfield, UK). Following removal of genomic DNA,
cDNA was produced using TaqMan MultiScribe reverse transcription reagents (Life Technolo-
gies). TaqMan gene expression assays were then used according to the manufacturer’s instruc-
tions to measure transcript expression of genes important for bone regeneration. These were
bone morphogenic protein 2 (BMP-2) an essential mediator of fracture healing [42], vascular
endothelial growth factor C (VEGFC) an important stimulator of angiogenesis [43], Collagen
type I alpha 2 (COL1A2) and osteonectin (SPARC) two factors involved in matrix deposition
and mineralisation [34] and Stromal derived factor 1 (CXCL12) a chemokine capable of influ-
encing chemotaxis of a wide range of cell types including MSCs [44,45]. Transcript expression
was measured relative to the housekeeping gene hypoxanthine-guanine phosphoribosyltrans-
ferase (HPRT) in three matched samples, Pre and Post enrichment, from each tissue.
Statistics
The Mann-Whitney U test was used for comparison of CD271-MSCs and PA-MSC character-
istics. The Spearman rank correlation coefficient was used to assess statistical dependence be-
tween CD271 and CD73 expression on uncultured BMMSCs. SPSS version 21 (IBM) was used
to calculate all statistics, GraphPad Prism 6 (GraphPad Software) was used to generate all
graphs. All bar charts show mean (bar height) and standard deviation.
Results
Enrichment of MSCs from BM aspirates using clinical-grade CD271
beads
Previous work investigating the functionality of CD271-enriched BMMSCs, in terms of mor-
phology, immunophenotype and tri-lineage potential, has employed research-grade anti-
CD271 microbeads [17,24,46]. Here, we assessed the suitability of clinical-grade CD271
microbeads to isolate functionally competent MSCs. CD271-MSC and PA-MSC exhibited sim-
ilar spindle-shaped fibroblastoid morphology and growth kinetics over the first three passages
and showed no significant difference in population doubling times (Fig. 1A). CD271-MSC and
PA-MSC also displayed equal positivity for CD73, CD90 and CD105 while lacking expression
of the HLA-DR as well as CD14, CD19, CD34 and CD45 (termed Lin) over the first three pas-
sages (Fig. 1B), conforming to the classical MSC phenotype [37]. Given that magnetic bead
technology relies on binding of microbeads to surface CD271 molecules, there is a possibility
that this could compromise further binding of ‘detection’ anti-CD271 antibodies. Furthermore,
transient binding of microbeads could also result in internalisation of the CD271 molecule
[47]; both factors could therefore affect MSC purity determination post-selection. To account
for this, we assessed the value of another MSC-specific molecule: CD73 as an alternative mark-
er for quantification of MSCs before and after CD271-based selections [16,19]. The frequencies
Clinical-Grade Isolation of Uncultured Mesenchymal Stromal Cells
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of CD45−/lowCD73+ population (Fig. 1C) and the CD45−/lowCD271+ population (Fig. 1D)
were measured in parallel in BM aspirates and the correlation between these two populations
was examined (Fig. 1E). A remarkably high degree of correlation (R = 0.985, p<0.001) indi-
cated the validity of measuring CD45−/lowCD73+ cells to assess the MSC purity after CD271
selection.
Immunomagnetic enrichment for MSCs using the CliniMACS system and clinical grade
CD271-based microbeads was first assessed using BM aspirates (n = 3 donors). Due to volume-
related limitations with the starting material (20ml of aspirate collected using an optimized
technique), CFU-F assays were not performed in these experiments and MSC purity was as-
sessed by analysis of the CD45-/lowCD73+ cells (Fig. 1F). The proportion of CD45−/lowCD73+
cells before separation (Pre) was 0.078%, consistent with previously published data [19]; it in-
creased to 14.5% following enrichment, thus representing a 186-fold increase (Fig. 1F). To ad-
dress our concern regarding the binding of ‘detection’ anti-CD271 antibodies to positively-
selected cells, the CD271 antibody was also added to the cocktail and the double-positive
(CD45−/lowCD73+CD271+) population was additionally measured. The proportion of double-
positive cells increased from 0.066% to 13.5% representing a 204-fold increase (Fig. 1G). This
indicated that microbead binding to the CD271 molecule on the surface of MSCs did not sig-
nificantly affect binding of the anti-CD271 ‘detection’ antibodies.
Total cell viability was not substantially compromised by the enrichment process (Fig. 1H).
CD45+ leucocytes [48] represent the majority of cells in BM aspirates. Before enrichment, they
represented 80.3% of total cells and although they were substantially depleted following selection,
there was still a considerable proportion remaining in the Post fraction (18.7%, Fig. 1I). BM con-
tains a significant portion of cells that express CD271 at a low level as well as CD45
(CD45+CD271low) [23, 26], illustrated on Fig. 1D, small box. Contamination of the positive frac-
tion with this ‘passenger’ cell type was anticipated. There was however, a relatively modest 15-
fold increase in this population from a 0.48% to 7.10% (Fig. 1J). This was quite remarkable since
these ‘passenger’ cells are approximately 3-fold more numerous than CD45−/lowCD271+ cells in
BM [16]. An extended phenotypic analysis of these ‘passenger’ cells confirmed the lack of expres-
sion of classical positive markers of BMMSCs such as CD73, CD90 and CD105. ‘Passenger’ cells
also lacked expression of MSCA-1 and SUSD2; whereas, CD34 and CD31 were expressed at vari-
able levels (Fig. 1K). Other contaminating cells present following enrichment included low levels
of T-cells (3.8%), B-Cells (3.7%), monocytes (4.5%) and endothelial cells (3.0%).
Enrichment of MSCs from intra-osseous surgical waste materials using
clinical-grade CD271 beads
Since obtaining large volumes of high-quality aspirates is problematic, we next evaluated clini-
cal-grade MSC isolation procedures using alternative sources of intra-osseous MSCs. Using
Fig 1. CD271-based enrichment of MSCs from BM aspirates.Comparison of the morphology (x10
magnification) and population doubling time between PA-MSC (open bars) and CD271-MSC isolated using
the QuadraMACS system (closed bars, n = 5); Bar charts showmeans + SEM (A). Immunophenotypic
analysis of PA-MSC (open bars n = 5) and CD271-MSC (closed bars) from passage 1 to passage 3. (Lin
corresponds to a cocktail of CD14, CD34, CD45 and CD19) (B). Representative dot plots generated from a
single BM aspirate showing the CD45−/lowCD73+ population (box) (C), the CD45−/lowCD271+ population
(large box) and the CD45+CD271low population (small box) (D). The relationship between the proportion of
CD45−/lowCD73+ and CD45−/lowCD271+ cells (23 separate BM aspirates collected from 12 donors) (E). The
proportion of CD45−/lowCD73+ (F) and CD45−/lowCD73+CD271+ (G) cells, pre and post CliniMACS
enrichment with representative dot plots below (n = 3). The proportion of total live cells (H) and CD45+
leukocytes (I) pre and post CliniMACS enrichment. The proportion of CD45+CD271low ‘passenger’ cells (J),
pre and post enrichment and a detailed analysis of ‘passenger cell’ phenotype (K). (Data F-K, n = 3)
doi:10.1371/journal.pone.0117855.g001
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cells enzymatically-released from FHs as a starting material, we observed that CD45−/lowCD73+
cells increased by of 8.2-fold from 7.3% in the Pre fraction to 60.0% in the Post fraction
(Fig. 2A). The same trends were observed for the double-positive CD45−/lowCD73+CD271+ pop-
ulation (14-fold increase, from 3.7% to 52.5%, Fig. 2B). Additional confirmation was provided
by CFU-F assay that showed a 9.9-fold increase in the proportion of colony-forming cells
(Fig. 2C), giving a mean total 2.4x105 CFU-F in the Post fraction. Similar to our experiments
with BM aspirates, a smaller 3.8-fold increase was found in the proportion of CD45+CD271low
‘passenger’ cells (from 1.4% to 5.5%, Fig. 2D). Other contaminating cells included T-cells (3.0%),
B-cells (5.1%), monocytes (0.7%) and endothelial cells (2.7%). CD45+ leucocytes were depleted
by 3.3-fold from 67.8% to 20.3% (Fig. 2E). Finally, a slight decrease in cell viability was observed
from 89.4% to 74.6% (Fig. 2F), possibly as a result of increased storage, exposure to the enzyme
and corresponding processing time.
Enrichment was also performed using cells collected in RIA waste fluid, surgical proce-
dure for obtaining RIA waste fluid is shown on Fig. 3A. Following CliniMACS enrichment,
CD45−/lowCD73+ cells increased by 163-fold from 0.25% to 40.8% (Fig. 3B); this was sup-
ported by measurements of double-positive cells, which increased by 304-fold, from 0.11%
to 35.0% (Fig. 3C). CFU-F assay confirmed significant MSC enrichment and showed a 173-
fold increase in the proportion of colony-forming cells (Fig. 3D), giving a total of 1.2x104
CFU-Fs in the Post fraction. The number of contaminating cells was low, including T-cells
(2.2%), B-cells (4.3%), monocytes (1.5%) and endothelial cells (1.8%). The proportion of
Fig 2. CD271-based enrichment of MSCs from discarded femoral heads. The proportion of CD45−/
lowCD73+ (A) and CD45−/lowCD73+CD271+ (B) cells, from enzymatically digested femoral heads pre and post
CliniMACS enrichment with representative dot plots below. The proportion of CFU-Fs pre and post
CliniMACS enrichment with representative images of CFU-F dishes below (C). The proportion of
CD45+CD271low ‘passenger’ cells (D), CD45+ leukocytes (E) and total live cells (F) pre and post CliniMACS
enrichment. (All data n = 3).
doi:10.1371/journal.pone.0117855.g002
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CD45+CD271low ‘passenger’ cells increased 76-fold, from 0.2% to 18.2% (Fig. 3E) and CD45+
leucocytes were depleted by 2.5-fold (Fig. 3F). There was no substantial decrease in cell via-
bility (Fig. 3G).
Altogether these data showed that the best MSC purities and yields were achieved using FH as
a starting material, where the initial proportions of MSCs were the highest. RIA waste fluid, on
the other hand, gave better cell viability but lower degrees of MSC purity and total MSC number.
Phenotypic and functional characteristics of CD271 enriched MSCs from
BM, FH and RIA
The functional and phenotypic characteristics of CD271 selected cells from BM, FH and RIA
were compared next. In every case CD271 selection resulted in the isolation of cells capable of
Fig 3. CD271-based enrichment of MSCs from RIA waste fluid. Inter-operative images of the RIA device
showing the main body of the device (left panel), the reamer head passing through the intramedullary canal
(middle panel) and the waste fluid collection bag (right panel) (A). The proportions of CD45−/lowCD73+ (B)
and CD45−/lowCD73+CD271+ cells (C) in RIA waste fluid pre and post CliniMACS enrichment, with
representative dot plots shown below. The proportion of CFU-Fs pre and post CliniMACS enrichment and
representative CFU-F dishes below (D). The proportion of CD45+CD271low ‘passenger’ cells (E), CD45+
leukocytes (F) and total live cells (G) pre and post CliniMACS enrichment. (All data n = 3).
doi:10.1371/journal.pone.0117855.g003
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osteogenic, adipogenic and chondrogenic differentiation (Fig. 4A-C). Differentiation capacity
was comparable to MSCs selected by plastic adherence as assessed by positive staining using al-
kaline phosphatase/von Kossa, Oil Red O and Alcian Blue respectively.
Fig 4. Functional analysis, phenotypic profile and transcripts expression of CD271 selected MSCs
from BM, FH and RIA.Differentiation potential of PA-MSCs and CD271-MSCs. Osteogenesis, adipogenesis
and chondrogenesis was measured on day-21 post-induction by staining with alkaline phosphatase/von
Kossa, Oil Red O and Alcian Blue, respectively in cells selected from BM (A), FH (B) and RIA (C), all size
bars represent 500μm. Phenotypic analysis of the CD45−/lowCD271+ population observed in BM (D), FH (E)
and RIA (F). Analysis of the total expression of BMP-2, COL1A2, VEGFC, SPARC and CXCL12 transcripts
relative to HPRT in BM (G), FH (H) and RIA (I) pre (black bars) and post (grey bars) CD271 enrichment. (All
data n = 3).
doi:10.1371/journal.pone.0117855.g004
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Analysis of the extended phenotype of CD45−lowCD271+ MSCs revealed a high degree of
similarity with regard to the expression of the classical phenotypic markers of MSCs. CD45−low
CD271+ cells in all tissues did not express CD14, CD19 and CD34 and had high expression of
CD73, CD90 and CD105 (Fig. 4D-E). Two proposed alternative markers for MSC enrichment
MSCA-1 and SUSD2 were highly expressed on CD45−low CD271+ cells from the BM (mean of
90% and 91% respectively, Fig. 4D). However, in FH the proportion of cells expressing MSCA-
1 and SUSD2 fell to 66.1 and 63.3, respectively (Fig. 4E). In RIA fluid MSCA-1 was highly ex-
pressed on CD45−low CD271+ cells (87.4%), but this was not the case for SUSD2 (63.25%,
Fig. 4F).
Altogether, these data confirmed that the selection of MSCs using clinical-grade CD271
microbeads resulted in the isolation of native MSCs with classical MSC functional and
phenotypic characteristics.
CD271 selected fractions express elevated levels of transcripts
important in bone regeneration
Relative expression of BMP-2 transcript was increased (mean of 311-fold) by CD271 enrich-
ment from BM (Fig. 4G). For VEGFC, an even higher level of enrichment (733-fold) was ob-
served. COL1A2 and SPARC were also highly enriched (687- and 42-fold respectively)
(Fig. 4G). Finally, the relative expression of CXCL12 was increased by the greatest degree fol-
lowing CD271 enrichment from BM (1381-fold, Fig. 4G). The expression of these transcripts
were uniformly increased in FH although to a lesser degree (Fig. 4H), possibly reflecting much
higher initial MSC content in this tissue, and therefore higher initial relative expression. Tran-
script levels in RIA fluid pre and post enrichment closely resembled those in BM (Fig. 4I).
In summary, CD271 selection led to substantially increased expression levels of BMP-2,
VEGFC, COL1A2, SPARC and CXCL12 transcripts.
Discussion
This study is the first assessment of a CD271-based GMP compliant immunomagnetic enrich-
ment procedure to isolate uncultured MSCs for their use in bone repair applications. In every
case the selection procedure resulted in a substantial increase in MSC purity and was accompa-
nied by an increased expression of transcripts directly involved in bone formation and vascu-
larisation. Overall, our data demonstrated the feasibility to successfully enrich functionally
competent MSCs using an appropriate marker, appropriate device and appropriate procedure
for clinical use. We also provided the first evidence supporting the possibility and feasibility to
acquire clinically-relevant numbers of uncultured and functionally viable MSCs from discarded
FHs or RIA fluids for their future autologous use.
We found that cultures initiated with CD271-selected cells were similar to plastic adherence
selected cultures from the same donors, consistent with observations by Poloni et al [49] and
extended these observations to CD271-selected MSCs from FHs and RIA fluids. Both plastic
adherence and CD271 selected cultures possessed classical MSC phenotype [37] and were ca-
pable of tri-lineage differentiation in vitro. In vivo bone forming capacity of CD271 derived cul-
tures has been demonstrated in previous studies [23,50].
Although we observed that cells expressing the CD45-/lowCD271+ phenotype in all three tis-
sues shared very similar expression levels of standard MSC markers such as CD73, CD105 and
CD90 [37], we were aware that tissue residence (i.e. within trabecular or cortical bone) could
have an additional impact on their in vivo composition [50–52]. To assess potential differences
in MSCs selected from BM aspirates, FHs and RIA, we investigated the relative expression of
two additional markers that have been suggested to offer highly specific selection for MSCs in
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BM, MSCA-1 and SUSD2 [38,39]. We confirmed the findings by the Buhring group that
in BM aspirates MSCA-1 and SUSD2 were both uniformly and specifically expressed on
CD45−/lowCD271+ cells (i.e. were not expressed outside of the CD45−/lowCD271+ popula-
tion). However, in FH and RIA preparations, a significant proportion of CD45−/lowCD271+
cells lacked expression of either MSCA-1 or SUSD2. It is therefore possible that in BM aspi-
rates these markers may offer superior selectivity for MSCs by avoiding collection of the ‘pas-
senger cell’ population however we believe that such MSCA-1 or SUSD2-based selection
could in fact miss out some MSCs, if FHs or RIA fluids are used as a starting material. Re-
garding the enrichment of CD45+CD271low ‘passenger’ cells in general, in all cases these
were enriched to a lesser degree than CD45−/lowCD73+ MSCs or CFU-Fs, suggesting that
clinical-grade CD271 microbeads preferentially selected for MSCs, which express higher lev-
els of CD271 [16,23]. The presence of other contaminating cells, which could potentially elic-
it an immune response, indicated that further improvements in this technology would be
required to consider the use of such isolates in allogeneic settings.
In terms of autologous applications, it is the dose and volumetric concentration of MSCs,
rather than their purity, appears to be critical. Hernigou et al showed that successful treatment
of fracture non-union, by percutaneous injection of concentrated BM, was associated with an
average total dose of 30,000 MSCs, measured by CFU-F assay at a concentration of1000
CFU-Fs/ml [53]. The advantage of MSCs enriched using the CliniMACS system in this context
is that the Post-fraction can be re-suspended in any final volume making concentrations of
over 1000 CFU-Fs/ml easily attainable. Up to now the direct engraftment, proliferation and dif-
ferentiation of MSCs injected into the fracture site has not been demonstrated however it is
very plausible that injected cells exert their regenerative by the release of trophic factors
[54,55], rather than extensive in situ expansion and differentiation. A possibility underlined by
our findings showing a substantial increase in VEGF and SDF-1 post CD271 enrichment.
With over 71,000 total hip replacements performed annually in England andWales alone
[56], FHs offer an abundant readily available alternative to BM. However, the osteoarthritic en-
vironment in which these MSC reside may affect their functionality [57,58] and be a factor lim-
iting their clinical allogeneic use. In comparison, reaming waste fluid represents a more
attractive MSC source for future applications; it does not require enzymatic digestion for MSC
extraction [33], and offers large volumes of easily obtainable, MSC-rich material that is cur-
rently discarded but could be used immediately or banked for the manufacture of high-purity
MSC isolates. It must be noted that any MSC preparation is subject to patient related factors
known to affect MSC potency such as donor age [8] and these should be taken into account
when considering RIA-fluids for MSC therapy. Although the total MSC content following en-
richment from RIA fluids was lower than anticipated (an average of 12,000 MSCs measured by
CFU-F assay), we believe it can be significantly improved by further optimising fluid collection
and tissue handling, including more rigorous anti-clotting measures.
In summary, the utility and commercial viability of MSC-based therapies for bone regenera-
tion and in broader therapeutic settings, with or without culture expansion, are dependent on
several factors the most salient of these are: safety, purity, cost and time required for processing
(Table 2). The clinical uptake of novel therapeutic interventions based on culture-expanded
MSCs is currently impeded by high regulatory demands and cost implications. CD271-based
MSC selection from RIA waste fluids would significantly increase both MSC numbers and
their purities and as such represents the most viable route for the clinical use of uncultured
MSCs in the autologous settings.
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